| STUDY |
Genomics companies have recognized "they can't thrive solely by licensing their particular technology and expertise for drug development by others," says consulting firm Ernst & Young in its 2002 biotech industry report. "To maximize the value of their technologies, many of them are venturing into the more risky and more expensive business of developing, and in some cases marketing, their own drugs." |
| UPDATE | 10.02 |
| COMPANY | Ernst & Young |
| LITERATURE REF. | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |